Prosecution Insights
Last updated: September 25, 2026

Maruzen Pharmaceuticals Co. Ltd.

Technology area: Biotechnology & Pharmaceuticals

4 pending office actions • 1 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Portfolio Summary

4
Total Pending OAs
3
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (75%)
0
Medium (0%)
0
Easy (0%)
1
Unknown (25%)

Rejection Statute Mix

BucketCases
§101 + other2 (50%)
Multi-statute (no §101)1 (25%)
No statute on record1 (25%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
25% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
3
Business / Other
75% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KUCHARCZK, JED A 1 80.2% +16.7%
MELLER, MICHAEL V 1 47.1% +28.2%
YOO, SUN JAE 1 71.0% +0.3%
DEKARSKE, MADELINE MCGUIRE 1 0.0% +0.0%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18864263 PARASYMPATHETIC NERVE ACTIVATION AGENT AND PARASYMPATHETIC NERVE ACTIVATION COMPOSITION KUCHARCZK, JED A —
18846440 ANTI-OBESITY AGENT AND ANTI-OBESITY COMPOSITION MELLER, MICHAEL V —
18560211 ORAL COMPOSITION, SKIN COSMETIC AND HAIR COSMETIC DEKARSKE, MADELINE MCGUIRE —

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18864263 PARASYMPATHETIC NERVE ACTIVATION AGENT AND PARASYMPATHETIC NERVE ACTIVATION COMPOSITION KUCHARCZK, JED A —
18846440 ANTI-OBESITY AGENT AND ANTI-OBESITY COMPOSITION MELLER, MICHAEL V —

Top Art Units

Art UnitApps
1622 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18864263 PARASYMPATHETIC NERVE ACTIVATION AGENT AND PARASYMPATHETIC NERVE ACTIVATION COMPOSITION KUCHARCZK, JED A — §101§102Other Non-Final OA — Pending Nov 08, 2024
18846440 ANTI-OBESITY AGENT AND ANTI-OBESITY COMPOSITION MELLER, MICHAEL V — §101§102§103 Non-Final OA — Pending Sep 12, 2024
18701698 AMPK ACTIVATOR, MOTOR FUNCTION IMPROVING AGENT, MUSCULAR ENDURANCE IMPROVING AGENT, AND MUSCLE ATROPHY PREVENTING AGENT YOO, SUN JAE — — Non-Final OA — Pending Apr 16, 2024
18560211 ORAL COMPOSITION, SKIN COSMETIC AND HAIR COSMETIC DEKARSKE, MADELINE MCGUIRE 1622 §102§103 Final Rejection — Pending Nov 10, 2023

Managing Maruzen Pharmaceuticals Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month